- Home
- TLSI vs YMAB Comparison
TLSI vs YMAB Comparison
Compare TLSI & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- YMAB
- Stock Information
- Founded
- TLSI 2010
- YMAB 2015
- Country
- TLSI United States
- YMAB United States
- Employees
- TLSI N/A
- YMAB N/A
- Industry
- TLSI Medical Specialities
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- TLSI Health Care
- YMAB Health Care
- Exchange
- TLSI Nasdaq
- YMAB Nasdaq
- Market Cap
- TLSI 204.0M
- YMAB 192.4M
- IPO Year
- TLSI N/A
- YMAB 2018
- Fundamental
- Price
- TLSI $5.54
- YMAB $4.33
- Analyst Decision
- TLSI Strong Buy
- YMAB Buy
- Analyst Count
- TLSI 5
- YMAB 11
- Target Price
- TLSI $10.90
- YMAB $17.55
- AVG Volume (30 Days)
- TLSI 39.7K
- YMAB 207.9K
- Earning Date
- TLSI 08-13-2025
- YMAB 08-11-2025
- Dividend Yield
- TLSI N/A
- YMAB N/A
- EPS Growth
- TLSI N/A
- YMAB N/A
- EPS
- TLSI N/A
- YMAB N/A
- Revenue
- TLSI $32,141,000.00
- YMAB $88,658,000.00
- Revenue This Year
- TLSI $55.52
- YMAB N/A
- Revenue Next Year
- TLSI $54.76
- YMAB $15.15
- P/E Ratio
- TLSI N/A
- YMAB N/A
- Revenue Growth
- TLSI 46.20
- YMAB 4.92
- 52 Week Low
- TLSI $3.50
- YMAB $3.55
- 52 Week High
- TLSI $6.08
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- TLSI 53.07
- YMAB 46.67
- Support Level
- TLSI $5.18
- YMAB $4.46
- Resistance Level
- TLSI $5.54
- YMAB $4.98
- Average True Range (ATR)
- TLSI 0.32
- YMAB 0.33
- MACD
- TLSI 0.01
- YMAB -0.05
- Stochastic Oscillator
- TLSI 82.81
- YMAB 7.77
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.